Citi has maintained a Buy rating on Torrent Pharmaceuticals, raising its target price to ₹4,380, implying an upside of approximately 20.7% from the current market price of ₹3,630.00.
The brokerage noted that Torrent delivered a healthy and in-line quarter, with strong momentum across branded markets, particularly in India and Brazil. Although there was a temporary supply disruption in Germany, it did not materially impact overall performance.
Torrent reported an adjusted EBITDA margin of 32.9%, which the company believes will serve as the minimum margin level in the coming quarters. Citi sees further margin expansion ahead, driven by operating leverage in branded segments and a potential recovery in the U.S. business.
Disclaimer: This article is based on Citi’s brokerage report and does not constitute investment advice. Please consult a certified financial advisor before making any investment decisions.
